| Published Application/Species/Sample/Dilution | Reference |
|---|
- immunohistochemistry - paraffin section; human; 1:50
| Gurzu S, Kádár Z, Sugimura H, Bara T, Hălmaciu I, Jung I. Gastric cancer in young vs old Romanian patients: immunoprofile with emphasis on maspin and mena protein reactivity. APMIS. 2015;123:223-33 pubmed publisher |
- immunohistochemistry; human; 1:100
| Gurzu S, Ciortea D, Tamasi A, Golea M, Bodi A, Sahlean D, et al. The immunohistochemical profile of granular cell (Abrikossoff) tumor suggests an endomesenchymal origin. Arch Dermatol Res. 2015;307:151-7 pubmed publisher |
- immunohistochemistry - paraffin section; human; 1:100
| Koppensteiner R, Samartzis E, Noske A, von Teichman A, Dedes I, Gwerder M, et al. Effect of MRE11 loss on PARP-inhibitor sensitivity in endometrial cancer in vitro. PLoS ONE. 2014;9:e100041 pubmed publisher |
| Ribeirinho Soares S, Pádua D, Amaral A, Valentini E, Azevedo D, Marques C, et al. Prognostic significance of MUC2, CDX2 and SOX2 in stage II colorectal cancer patients. BMC Cancer. 2021;21:359 pubmed publisher |
| Noh B, Kwak J, Eom D. Immune classification for the PD-L1 expression and tumour-infiltrating lymphocytes in colorectal adenocarcinoma. BMC Cancer. 2020;20:58 pubmed publisher |
| Eriksen A, Sørensen F, Lindebjerg J, Hager H, dePont Christensen R, Kjær Frifeldt S, et al. Programmed Death Ligand-1 expression in stage II colon cancer - experiences from a nationwide populationbased cohort. BMC Cancer. 2019;19:142 pubmed publisher |
| Hansen T, Kjær Frifeldt S, Eriksen A, Lindebjerg J, Jensen L, Sørensen F, et al. Prognostic impact of CDX2 in stage II colon cancer: results from two nationwide cohorts. Br J Cancer. 2018;119:1367-1373 pubmed publisher |
| Valtcheva N, Lang F, Noske A, Samartzis E, Schmidt A, Bellini E, et al. Tracking the origin of simultaneous endometrial and ovarian cancer by next-generation sequencing - a case report. BMC Cancer. 2017;17:66 pubmed publisher |
| Brandt S, Samartzis E, Zimmermann A, Fink D, Moch H, Noske A, et al. Lack of MRE11-RAD50-NBS1 (MRN) complex detection occurs frequently in low-grade epithelial ovarian cancer. BMC Cancer. 2017;17:44 pubmed publisher |
| Knudsen K, Nielsen B, Lindebjerg J, Hansen T, Holst R, Sørensen F. microRNA-17 Is the Most Up-Regulated Member of the miR-17-92 Cluster during Early Colon Cancer Evolution. PLoS ONE. 2015;10:e0140503 pubmed publisher |
| Dawson H, Koelzer V, Lukesch A, Mallaev M, Inderbitzin D, Lugli A, et al. Loss of Cdx2 Expression in Primary Tumors and Lymph Node Metastases is Specific for Mismatch Repair-Deficiency in Colorectal Cancer. Front Oncol. 2013;3:265 pubmed publisher |
